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Abstract Human epidermal growth factor receptor 2 (HER2)
amplification/overexpression is an effective therapeutic target
in breast and gastric cancer. Although HER2 positivity has
been reported in other malignancies, previous studies gener-
ally focused on one cancer type, making it challenging to
compare HER2 positivity across studies/malignancies. Here-
in, we examined 37,992 patient samples for HER2 expression
(+/− amplification) in a single laboratory. All 37,992 patients
were tested by immunohistochemistry (IHC); 21,642 of them
were also examined for HER2 amplification with either fluo-
rescent in situ hybridization (FISH) (11,670 patients) or chro-
mogenic in situ hybridization (CISH) (9,972 patients); 18,262
patients had tumors other than breast or gastric cancer. All
tissues were analyzed in a Clinical Laboratory Improvement
Amendments (CLIA) laboratory (Caris Life Sciences) at the
request of referring physicians. HER2 protein overexpression
was found in 2.7 % of samples. Over-expressed HER2 was
detected predominantly in malignancies of epithelial origin;
for cancers derived frommesenchyme, neuroendocrine tissue,
central nervous system, and kidney, HER2 expression and
amplification were remarkably rare or non-existent. Bladder
carcinomas, gallbladder, extrahepatic cholangiocarcinomas,
cervical, uterine, and testicular cancers showed HER2 positiv-
ity rates of 12.4, 9.8, 6.3, 3.9, 3.0, and 2.4 %, respectively.
HER2 overexpression and/or amplification is frequently
found across tumor types. These observations may have sig-
nificant therapeutic implications in cancers not traditionally
thought to benefit from anti-HER2 therapies.
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1 Introduction
The oncogenic potential of human epidermal growth factor
receptor 2 (HER2) has been firmly established in preclinical
and clinical settings. Among all four HER family proteins,
HER2 has the strongest catalytic kinase activity and functions
as the most active signaling complex of the HER family after
dimerization with other HER family members [1, 2]. Overex-
pression of HER2 in breast cancer leads to increased
homodimerization (HER2:HER2) and heterodimerization
(e.g., HER2:HER3), which initiates a strong pro-tumorigenic
signaling cascade [3]. Overexpression of HER2 protein drives
malignant transformation in cell culture and transgenic mouse
models [4, 5]. The anti-HER2 antibody trastuzumab repre-
sents an effective, targeted therapy with significant efficacy
in treatment of HER2-positive breast and gastric cancer [6, 7].
Indeed, trastuzumab in combination with cisplatin and a
fluoropyrimidine (capecitabine or 5-fluorouracil) has been ap-
proved for the treatment of patients with HER2 overexpress-
ing metastatic gastric or gastroesophageal (GE) junction ade-
nocarcinoma, who have not received prior treatment for met-
astatic disease [8]. The latter approval is based on a significant
improvement in median overall survival (OS) of 2.5 months
with trastuzumab plus chemotherapy treatment compared to
chemotherapy alone, demonstrated in an international,
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multicenter, open-label, randomized clinical trial, BO18255
(ToGA trial) [6]. Furthermore, the family of approved anti-
HER2 agents has been expanding in recent years, with the
addition of small molecule inhibitors (e.g., lapatinib), antibod-
ies (pertuzumab), and an antibody-drug conjugate (ado-
trastuzumab emtansine, T-DM1). Used alone or in combina-
tion with other targeting agents or chemotherapy, these anti-
HER2 agents have remarkably improved the outcome of pa-
tients with HER2-positive breast cancer [9, 10].
Breast and gastric cancers cases demonstrate a substantial
HER2 protein overexpression by immunohistochemistry, pre-
dominantly driven by HER2 amplification at the DNA level.
The majority of studies of HER2-targeting therapies have been
focused on this group of HER2-positive breast or gastric cancer
cases. However, HER2 amplification/overexpression is known
to exist in a non-negligible subset of cancers outside of breast and
stomach. For example, approximately 15–37 % of salivary duct
carcinomas exhibit 3+ HER2 expression [11, 12]. Other malig-
nancies including, but not limited to, non-small cell lung
(NSCLC), ovarian, colon, and pancreatic cancer, overexpress
HER2 protein and/or exhibit gene amplification in a variable
percentage of cases [13, 14]. Additionally, mutations in HER2
have been described in a small subset of cancers of the breast,
lung, ovary, and colon [13]. Anecdotal reports of patients with
diverse cancers andHER2 amplification or mutation responding
to anti-HER2 agents have been published [15–18], implying a
potential role for anti-HER2 agents outside of breast and gastric
cancer.
Multiple reports of studies evaluating the percentage of HER2
positivity in individual cancer types have shed some light on the
distribution of HER2 positivity across individual cancer types
[13]; however, given a lack of standardized methodology and
interpretation criteria, it is challenging to compare the rate of
HER2 positivity across studies and tumor types. Herein, we
reviewed 37,992 patients with cancer, whose tumors were inter-
rogated for HER2 protein expression with or without amplifica-
tion in a single-lab setting. To our knowledge, this is the largest
database that allows examination of HER2 across diverse malig-
nancies. Overall, 2.7 % (1014/37,992) of all tumors tested dem-
onstrated HER2 positivity determined by immunohistochemistry
(IHC), and most types of cancer had a subset of patients, albeit
often small, who demonstrated HER2 positivity determined by
either in situ hybridization (ISH) and/or IHC. These data form the
foundation for possible studies that assess HER2 therapy in a
pan-cancer fashion.
2 Materials and methods
2.1 Tissue samples
Solid tumor specimens submitted to a commercial molecular
profiling laboratory (Caris Life Sciences, Phoenix, Arizona; a
CLIA, CAP, NYSDOH and ISO certified laboratory) were
initially evaluated for this retrospective analysis of HER2.
The pathologic diagnosis was obtained from the pathology
report provided by the outside lab and was further reviewed
and verified by board-certified pathologists at Caris. Tissue
requirements and detailed processing methods in collection
locations can be found in the Supplemental Methods. Multi-
platform profiling included immunohistochemistry and in situ
hybridization either by fluorescent in situ hybridization
(FISH) or chromogenic in situ hybridization (CISH). This
investigation was performed in accordance with UC San
Diego IRB guidelines.
2.2 Immunohistochemistry
IHC analysis was performed on formalin-fixed, paraffin-
embedded tissue utilizing the commercially available anti-
body PATHWAYanti-HER2 (4B5) rabbit monoclonal prima-
ry antibody (Ventana Medical Systems). All IHCs were per-
formed using commercially available detection kits and auto-
mated membranous staining techniques (Benchmark XT,
Ventana, USA). HER2 scoring was reported per American
Society of Clinical Oncology/College of American Patholo-
gists (ASCO/CAP) guidelines published in 2007 [14] and up-
dated in 2013 [19, 20]. For the purpose of our analysis, an IHC
test was considered positive (IHC+) when IHC3+ was obtain-
ed above the guidelines defined thresholds; an IHC test was
considered negative (IHC-) when IHC 2+ (equivocal), IHC
1+, or IHC 0 was obtained.
2.3 HER2 in situ hybridization
Among the 37,992 samples analyzed by IHC, 21,642 samples
were also examined with ISH. FISH was used for evaluation
of the HER2 amplification status. HER2/CEP17 ratio higher
than 2.2 was considered amplified [14] (ISH+), and
HER2/CEP17 ratio between 1.8 and 2.2 (equivocal) in FISH
or HER2/CEP17 ratio <1.8 in FISH was considered non-
amplified (ISH-). HER2 amplification was also evaluated by
CISH (INFORM HER2 dual ISH DNA probe cocktail,
Ventana). Consistent with the CISH package insert, HER2/
CEP17 ratio higher than 2.0 was considered amplified
(ISH+); HER2/CEP17 ratio <2.0 in CISH was considered
non-amplified (ISH-).
2.3.1 HER2 fluorescent in situ hybridization
FISH was performed with a probe specific for HER2
(17q11.2-q12 region) and a probe for the pericentromeric re-
gion of chromosome 17 (Abbott Molecular/Vysis). Interphase
nuclei were examined and the ratio of HER2 signals to chro-
mosome 17 centromere signals were evaluated to indicate
amplification status of this gene. The HER2 Pathvysion probe
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has been approved by the US Food and Drug Administration
for selection of patients for trastuzumab and pertuzumab
therapy.
2.3.2 HER2 chromogenic in situ hybridization
CISH was performed by using Ventana Medical Systems,
Inc.’s (Ventana) INFORMHER2Dual ISHDNAProbe Cock-
tail as intended to determine HER2 gene status by enumera-
tion of the ratio of the HER2 gene to chromosome 17. The
HER2 and chromosome 17 probes are detected using two
color ISH in formalin-fixed, paraffin-embedded human cancer
tissue specimens following staining on VENTANA Bench-
Mark XT automated slide stainer, and visualized by light mi-
croscopy. The INFORM HER2 Dual ISH DNA Probe Cock-
tail has been approved by the US Food and Drug Administra-
tion for selection of patients to HER2 targeted therapies in
breast cancer.
2.4 Statistical methods
Descriptive statistics were used. For Table 2, the concordance
between the IHC and ISH tests was calculated by dividing the
number of samples that had concordant results for both IHC
and ISH tests (IHC+ and ISH+; or IHC- and ISH-) by the total
number of samples within each malignancy types. JMPv10.0
(SAS Institute Inc., Cary, NC) was utilized.
3 Results
3.1 HER2 protein expression in various malignancies
As shown in Table 1 and Fig. 1, HER2 protein 3+ expression
by IHCwas demonstrated in a subset of virtually all examined
carcinomas derived from epithelial origin. The frequency
ranged from 0.4 % in hepatocellular carcinoma to 12.4 % in
bladder cancer. Table 3 gives examples of positivity rates
found in the literature. Interestingly, HER2 protein 3+ expres-
sion was very rare, often non-existent, in malignancies of non-
epithelial origin. In 965 melanoma samples, only one showed
HER2 3+ expression. In 1,211 sarcomas (soft tissues) and 1,
136 neuroendocrine tumors, none exhibited 3+ HER2 protein
expression. No HER2 3+ expression was detected in gastro-
intestinal stromal tumors (GIST), small cell lung cancers
(SCLC), kidney cancers, and glioblastomas.
3.2 HER2 positivity determined by IHC and ISH in various
malignancies
HER2 protein expression determined by IHC and HER2 gene
amplification determined by ISH were examined in a total of
21,642 samples. Consistent with HER2 protein expression
pattern, HER2 gene amplification was predominantly detected
in malignancies derived from epithelial origin and very rarely
found in cancers derived from other tissue origins; HER2
amplification was seen in only one out of 60 retroperitoneal/
peritoneal sarcomas, four out of 237 kidney cancers, and none
in GISTs (0/59), small cell lung cancers (0/108), or melano-
mas (0/388). A total of 705 samples were found to be HER2
positive by IHC; 638 (90.5 %) of them were also positive by
ISH testing. Among breast cancer cases, 286 samples tested
IHC+; 266 of them (93 %) were also positive by ISH. The
overall concordance rate (IHC+ and ISH+; or IHC- and ISH-)
between the two tests was 96.3 % (Table 2).
4 Discussion
Our recent review of the literature that examined HER2
amplification/overexpression in a variety of cancers outside
of breast and stomach [13] found that almost all studies fo-
cused on HER2 status in one type of malignancy, making it
difficult to compare the rate of HER2 positivity across studies
and tumor types. Herein, we have analyzed 37,992 patients
with cancer whose tumors were interrogated for HER2 protein
expression in a single, accredited laboratory setting. We report
that 2.7 % of all cancer samples demonstrated HER2 overex-
pression (3+ on IHC) (Table 1). To our knowledge, this is the
largest database that interrogated HER2 across diverse malig-
nancies. These observations provide a consistent comparison
of HER2 status between individual tumor types that could be
used to inform future trials of anti-HER2 therapy outside of
breast and stomach cancer. For example, the incidence of
HER2 overexpression by IHC in bladder cancers (12.4 %) is
even higher than that found in breast cancer (10.5 %) (Fig. 1),
suggesting that a trial of anti-HER2 agents may be warranted
in patients with advanced bladder cancer. HER2 overexpres-
sion by IHC was also substantial in gallbladder cancers
(9.8 %). When reviewing the literature, it was noticeable that
studies demonstrated variability in rates of HER2 overexpres-
sion (Table 3), making our results difficult to compare with
other published series. This variability can be explained by the
differing criteria used for the evaluation of HER2 positivity in
the studies found in the literature, due in part by the lack of
standardized methodology for HER2 detection outside of gas-
tric and breast cancers [13]. Of interest, we report that approx-
imately 10.5 % of breast cancer patients are HER2 positive by
IHC, which appears to be in the lower range when compared
to published reports (11–25 %, Table 3). Varga et al. [26]
investigated HER2 positivity in more than 7,000 patients with
breast cancers over a 12-year period and showed a drop in the
expression rate (probably due to the modified ASCO criteria
in 2007), which went from 22 to 12 % over the years. The
decrease in HER2 positivity rate can also potentially be ex-
plained by the introduction of mammography screening with
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improved detection of early breast cancers, as screen detection
resulted in a shift to a different patient population with less
HER2 positive cases in early breast cancer and with younger
age at diagnosis [39, 40]. Lastly, the lower percentage of
HER2 positivity rate in our study may be due to a higher
proportion of triple-negative breast cancer specimens sent to
the testing laboratory (35.8% (Caris, data on file) as compared
to 15–20 % of the general breast cancer population [19, 41]).
Due to the aggressive nature of triple-negative breast cancer, a
higher percentage may be evaluated for the molecular profil-
ing that generally is performed with HER2 testing in the lab-
oratory. One interesting pattern of HER2 positivity became
apparent with direct comparison of HER2 status across differ-
ent tumor types: overexpressed HER2 is predominantly found
Table 1 HER2 positivity by IHC
in diverse cancers (N=37,992) Malignancy type HER2 positive
(IHC 3+) samples (N)
Total no. of
samples
Percentage of
HER2 positivity (%)
• N>50 in each cancer type N=1013 N=37,864 2.7
Bladder cancers 59 475 12.4
Breast cancers 388 3706 10.5
Cervical cancers 23 585 3.9
Cholangiocarcinomas (extrahepatic) 5 80 6.3
Cholangiocarcinomas (intrahepatic) 2 321 0.6
Colorectal cancers 80 4507 1.8
Esophageal, esophagogastric junction cancers 71 628 11.3
Gallbladder cancers 19 194 9.8
Gastric adenocarcinomas 27 580 4.7
Gastrointestinal stromal tumors 0 143 0.0
Glioblastoma multiforme, high grade gliomas 0 763 0.0
Head and neck carcinomas 7 552 1.3
Hepatocellular carcinomas 1 245 0.4
Intestinal (small) malignancies 2 235 0.9
Kidney cancers 0 531 0.0
Lung cancers (non-small cells) 49 4609 1.1
Lung cancers (small-cells) 0 322 0.0
Melanomas 1 965 0.1
Melanomas (uveal) 0 54 0.0
Neuroendocrine tumors 0 1136 0.0
Ovarian (epithelial) cancers 122 7854 1.6
Ovarian (non-epithelial) cancers 1 279 0.4
Pancreatic adenocarcinomas 14 2072 0.7
Prostate cancers 2 350 0.6
Sarcomas (peritoneal, retroperitoneal) 0 106 0.0
Sarcomas (soft tissues) 0 1211 0.0
Thymic cancers 0 90 0.0
Thyroid cancers 0 158 0.0
Unknown primary cancers 29 1376 2.1
Uterine cancers 111 3737 3.0
• N<50 in each cancer type N=1 N=128 0.8
Gliomas (low-grade) 0 41 0.0
Oligodendrogliomas 0 18 0.0
Penile cancers 0 10 0.0
Pituitary cancers 0 6 0.0
Solitary fibrous tumors 0 12 0.0
Testicular cancers 1 41 2.4
Overall N=1014 N=37,992 2.7
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in malignancies of epithelial origin. For cancers derived from
mesenchyme, neuroendocrine tissue, central nervous system,
and kidney, HER2 expression and HER2 gene amplification
are negligible (Fig. 1).
HER2 gene amplification is the major mechanism driving
HER2 overexpression in breast cancer [39]. It has been noted
before that HER2 protein may not be consistently analyzed in
formalin-fixed tissues because of variations in methods and
duration of fixation, in comparison to ISH analysis that is less
dependent on tissue fixation methods [14, 39, 40]. Alterna-
tively, it is plausible that there are transcriptional or transla-
tional mechanisms that could attenuate HER2 expression in
some cases, even in the presence of amplification. The overall
(positive and negative) concordance rate between methodolo-
gies was about 96 % in our cohort, which is in accordance
with the American Society of Clinical Oncology/College of
American Pathologists guideline that any two diagnostic com-
panion tests should establish a concordance rate of >95 % for
positive and negative assay values [14]. Further, 90 % of all
samples and 93 % of breast cancer cases that were tested
HER2 positive by IHC, were also found positive by ISH. This
percentage stands in the higher range of what has been pub-
lished. For example, the positivity concordance rates (IHC+
tests also found positive by FISH) reported by different groups
ranged from 69 to 98%, with most of them being around 85%
[26, 41–43].
There are several limitations to our study. The current pool
of samples cover a wide range of malignancies but there may
be selection bias of the specimens, as patients/physicians may
have elected to submit tissue when there were fewer standard
therapeutic options left, and often for advanced and/or more
difficult to treat cancers (refractory and recurrent). Also, the
samples came from diverse institutes and practices, and dif-
ferences in processing and storage could still have affected
samples, even if the HER2 analysis itself was performed by
a single organization. Finally, the current study addressed
HER2 overexpression. It has recently been shown that
HER2 can demonstrate mutations in about 1.8 % of diverse
cancers (∼7300 solid tumor specimens tested) and that rear-
rangements can be seen, albeit very rarely (∼0.02 % of pa-
tients) [44]. In summary, we have examined 37,992 samples
for HER2 expression (with 21,642 of them also examined for
HER2 amplification) and profiled HER2 status across differ-
ent tumor types. Overall, 2.7 % of all cancers tested were IHC
3+ positive. High levels of HER2 were seen in a subset of
patients with most epithelial malignancies examined. For
non-epithelial cancers such as melanoma, GIST, small cell
lung cancers, and glioblastomas, almost no HER2 overexpres-
sion was discerned. Some tumors such as bladder, gallbladder,
and cholangiocarcinomas showed significant rates of HER2
positivity (greater than 5 %), and testicular, ovarian, uterine,
cervical, head and neck, non-small cell lung, and colorectal
cancer as well as tumors of unknown origin all showed small
but not negligible rates of positivity. Of additional interest, a
small percentage of tumors may also have HER2 mutations
that are amenable to targeted HER2 agents, and these patients
would not be expected to have high expression levels of
HER2 [13, 15–18]. An early histology-independent trial using
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lapatinib monotherapy for HER2-expressing tumors faced lo-
gistical challenges and showed only modest activity [45].
However, in the last several years, there has been increasing
experience with target-driven trials and overcoming their lo-
gistical challenges [46–48]. Our data presented herein, as well
as the advent of numerous, potent small molecule inhibitors,
antibodies and other agents that target HER2, suggest that it
may be worthwhile to enrich clinical trials using HER2-
targeting agents with patients that have HER2-positive tumors
other than breast and gastric.
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